Six-month hemoglobin concentration and its association with subsequent mortality among adults on antiretroviral therapy in Lusaka, Zambia

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 1, 2012, Pages 120-123

  Giganti, Mark J ^a,b   Limbada, Mohammed ^a   Mwango, Albert ^c   Moyo, Crispin ^c   Mulenga, Lloyd B ^a   Brad Guffey, M ^a,b   Mulenga, Priscilla L ^a   Bolton Moore, Carolyn ^a   Stringer, Jeffrey S A ^a,b   Chi, Benjamin H ^a,b  

^a CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MINISTRY OF HEALTH   (Zambia)

Author keywords

Africa; anemia; antiretroviral therapy; hemoglobin; HIV; Zambia

Indexed keywords

EFAVIRENZ; EMTRICITABINE; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HAZARD RATIO; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MICROCYTIC ANEMIA; MORTALITY; NORMOCHROMIC NORMOCYTIC ANEMIA; PRIORITY JOURNAL; ZAMBIA;

ADULT; ANEMIA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; MALE; SURVIVAL ANALYSIS; ZAMBIA;

EID: 84865712772     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825da11d     Document Type: Article

References (18)

1. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther. 2006;11:741-749.
2. Mugisha JO, Shafer LA, Van der Paal L, et al. Anaemia in a rural Ugandan HIV cohort: prevalence at enrolment, incidence, diagnosis and associated factors. Trop Med Int Health. 2008;13:788-794.
3. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782-793.
4. Kiragga AN, Castelnuovo B, Nakanjako D, et al. Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc. 2010;13:42.
5. World Health Organization. Worldwide Prevalence of Anaemia 1993-2005: Who Global Database on Anaemia. Geneva, Switzerland: WHO Press; 2008.
6. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006;20:1181-1189.
7. Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13: 959-967.
8. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.
9. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449-457.
10. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008;22:873-882.
11. Russell EC, Charalambous S, Pemba L, et al. Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health. 2010;10:433.
12. Moyle G, Sawyer W, Law M, et al. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther. 2004;26:92-97.
13. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007;298: 1888-1899.
14. Chi BH, Mwango A, Giganti M, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr. 2010;54:63-70.
15. National Institute of Allergy and Infectious Diseases. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0. Available at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/ Table-for-Grading-Severity-of-Adult-Pediatric-Adverse-Events.pdf. Accessed December 6, 2011.
16. Chi BH, Cantrell RA, Zulu I, et al. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol. 2009;38: 746-756.
17. Lewis DK, Whitty CJ, Walsh AL, et al. Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg. 2005; 99:561-567.
18. World Health Organization. Nutritional Anemias: Report of a WHO Scientific Group. WHO Technical Report Series 405. Geneva, Switzerland: World Health Organization; 1968:37.